Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and IIa clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease and cystic fibrosis. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:VRNA
CUSIPN/A
Phone44-20-3283-4200
Debt
Debt-to-Equity RatioN/A
Current Ratio6.11
Quick Ratio6.11
Price-To-Earnings
Trailing P/E Ratio-5.47
Forward P/E Ratio-5.17
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$7.84 per share
Price / Book1.68
Profitability
EPS (Most Recent Fiscal Year)($2.41)
Net Income$-26,410,000.00
Net MarginsN/A
Return on Equity-40.96%
Return on Assets-34.97%
Miscellaneous
Employees15
Outstanding Shares13,130,000
Market Cap$182.46 million
VERONA PHARMA P/S (NASDAQ:VRNA) Frequently Asked Questions
What is VERONA PHARMA P/S's stock symbol?
VERONA PHARMA P/S trades on the NASDAQ under the ticker symbol "VRNA."
When is VERONA PHARMA P/S's next earnings date?
What price target have analysts set for VRNA?
5 analysts have issued twelve-month target prices for VERONA PHARMA P/S's shares. Their forecasts range from $25.00 to $56.00. On average, they anticipate VERONA PHARMA P/S's share price to reach $34.80 in the next year. This suggests a possible upside of 164.0% from the stock's current price. View Analyst Price Targets for VERONA PHARMA P/S.
What is the consensus analysts' recommendation for VERONA PHARMA P/S?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for VERONA PHARMA P/S in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for VERONA PHARMA P/S.
Who are some of VERONA PHARMA P/S's key competitors?
Some companies that are related to VERONA PHARMA P/S include Inflarx (IFRX), Kura Oncology (KURA), Aptinyx (APTX), CymaBay Therapeutics (CBAY), Crinetics Pharmaceuticals (CRNX), Kiniksa Pharmaceuticals (KNSA), Epizyme (EPZM), Geron (GERN), ANI Pharmaceuticals Inc Common Stock (ANIP), Vectura Group (VEGPF), Abeona Therapeutics (ABEO), Urogen Pharma (URGN), Viking Therapeutics (VKTX), Adamas Pharmaceuticals (ADMS) and GlycoMimetics (GLYC).
Who are VERONA PHARMA P/S's key executives?
VERONA PHARMA P/S's management team includes the folowing people:
- Dr. Jan-Anders Karlsson, Chief Exec. Officer & Exec. Director (Age 63)
- Mr. Piers John Morgan MA, ACA, Chief Financial Officer (Age 52)
- Ms. Claire Louise Poll, Legal Counsel (Age 51)
- Dr. Peter Spargo Ph.D., Sr. VP of CMC (Age 56)
- Mr. Richard Hennings, Commercial Director (Age 48)
When did VERONA PHARMA P/S IPO?
(VRNA) raised $61 million in an initial public offering (IPO) on Thursday, April 27th 2017. The company issued 4,500,000 shares at a price of $13.49 per share. Jefferies and Stifel acted as the underwriters for the IPO and Wedbush PacGrow and SunTrust Robinson Humphrey were co-managers.
Has VERONA PHARMA P/S been receiving favorable news coverage?
News headlines about VRNA stock have been trending somewhat positive on Tuesday, according to Accern Sentiment. The research group identifies negative and positive media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. VERONA PHARMA P/S earned a daily sentiment score of 0.04 on Accern's scale. They also gave news articles about the company an impact score of 46.76 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the immediate future. View Recent Headlines for VERONA PHARMA P/S.
How do I buy shares of VERONA PHARMA P/S?
Shares of VRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is VERONA PHARMA P/S's stock price today?
One share of VRNA stock can currently be purchased for approximately $13.18.
How big of a company is VERONA PHARMA P/S?
VERONA PHARMA P/S has a market capitalization of $182.46 million. The company earns $-26,410,000.00 in net income (profit) each year or ($2.41) on an earnings per share basis. VERONA PHARMA P/S employs 15 workers across the globe.
How can I contact VERONA PHARMA P/S?
VERONA PHARMA P/S's mailing address is 3 MORE LONDON RIVERSIDE, LONDON X0, SE1 2RE. The company can be reached via phone at 44-20-3283-4200 or via email at [email protected]
MarketBeat Community Rating for VERONA PHARMA P/S (NASDAQ VRNA)
MarketBeat's community ratings are surveys of what our community members think about VERONA PHARMA P/S and other stocks. Vote "Outperform" if you believe VRNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VRNA will underperform the S&P 500 over the long term. You may vote once every thirty days.
